Disease Domain | Count |
---|---|
Nervous System Diseases | 3 |
Immune System Diseases | 2 |
Endocrinology and Metabolic Disease | 2 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Interferons | 1 |
AAV based gene therapy | 1 |
Synthetic peptide | 1 |
Interleukins | 1 |
Bacteriophage therapy | 1 |
Target- |
Mechanism Immunomodulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism IL-6R agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism IFNAR agonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date05 Nov 2023 |
Sponsor / Collaborator Wingate Institute [+1] |
Start Date01 Nov 2023 |
Sponsor / Collaborator |
Start Date25 May 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Atexakin alfa ( IL-6RA ) | Peripheral Nervous System Diseases More | Phase 2 |
Edratide | Systemic Lupus Erythematosus More | Phase 2 |
Interferon beta-1a extended release(Weizmann Institute of Science) ( IFNAR ) | Multiple Sclerosis More | Phase 1 |
VF-166 | Neoplasms More | Preclinical |
Gba1 gene therapy (Lysogene/Weizmann Institute of Science) | Gaucher Disease More | Preclinical |